8-K Announcements
6May 5, 2026·SEC
Mar 16, 2026·SEC
Mar 4, 2026·SEC
Viemed Healthcare, Inc. (VMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Viemed Healthcare, Inc. (VMD) stock price & volume — 10-year historical chart
Viemed Healthcare, Inc. (VMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Viemed Healthcare, Inc. (VMD) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.06vs $0.09-33.3% | $75Mvs $74M+1.4% |
| Q2 2026 | Mar 4, 2026 | $0.14vs $0.12+16.7% | $76Mvs $78M-2.0% |
| Q4 2025 | Nov 5, 2025 | $0.09vs $0.09+0.0% | $72Mvs $78M-7.4% |
| Q3 2025 | Aug 6, 2025 | $0.08vs $0.09-5.9% | $63Mvs $64M-0.7% |
Viemed Healthcare, Inc. (VMD) competitors in Respiratory and sleep therapy devices — business model, growth, and fundamentals comparison
Viemed Healthcare, Inc. (VMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Viemed Healthcare, Inc. (VMD) annual income statement — 10-year revenue, gross profit & net income history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 46.93M | 65.27M | 80.26M | 131.31M | 117.06M | 138.83M | 183.01M | 224.26M | 270.28M | 286.56M |
| Revenue Growth % | 49.66% | 39.09% | 22.96% | 63.61% | -10.85% | 18.6% | 31.82% | 22.54% | 20.52% | 23.1% |
| Cost of Goods Sold | 12.31M | 16.69M | 24.25M | 51.2M | 43.65M | 54.15M | 70.22M | 91.05M | 114.82M | 121.91M |
| COGS % of Revenue | 26.24% | 25.57% | 30.22% | 38.99% | 37.29% | 39.01% | 38.37% | 40.6% | 42.48% | - |
| Gross Profit | 34.62M▲ 0% | 48.58M▲ 40.3% | 56.01M▲ 15.3% | 80.11M▲ 43.0% | 73.41M▼ 8.4% | 84.68M▲ 15.4% | 112.78M▲ 33.2% | 133.2M▲ 18.1% | 155.46M▲ 16.7% | 164.65M▲ 0% |
| Gross Margin % | 73.76% | 74.43% | 69.78% | 61.01% | 62.71% | 60.99% | 61.63% | 59.4% | 57.52% | 57.46% |
| Gross Profit Growth % | 83.55% | 40.35% | 15.28% | 43.04% | -8.36% | 15.35% | 33.19% | 18.11% | 16.71% | - |
| Operating Expenses | 20.65M | 31.54M | 47.15M | 53.33M | 61.83M | 76.43M | 98.45M | 115.3M | 134.75M | 137.91M |
| OpEx % of Revenue | 44% | 48.32% | 58.75% | 40.61% | 52.82% | 55.05% | 53.8% | 51.42% | 49.85% | - |
| Selling, General & Admin | 20.25M | 30.95M | 45.27M | 57.71M | 60.04M | 73.36M | 93.73M | 112.48M | 130.5M | 134.5M |
| SG&A % of Revenue | 43.14% | 47.42% | 56.4% | 43.95% | 51.29% | 52.84% | 51.22% | 50.16% | 48.28% | - |
| Research & Development | 0 | 0 | 848K | 1.08M | 2.11M | 2.7M | 2.78M | 3.07M | 3.02M | 2.8M |
| R&D % of Revenue | - | - | 1.06% | 0.82% | 1.8% | 1.94% | 1.52% | 1.37% | 1.12% | - |
| Other Operating Expenses | 402K | -71K | 1.03M | -5.46M | -323K | 369K | 1.94M | -249K | 1.23M | 607K |
| Operating Income | 8.82M▲ 0% | 17.05M▲ 93.2% | 8.86M▼ 48.0% | 26.78M▲ 202.4% | 11.58M▼ 56.8% | 8.25M▼ 28.7% | 14.33M▲ 73.7% | 17.9M▲ 24.9% | 20.71M▲ 15.7% | 23.59M▲ 0% |
| Operating Margin % | 18.8% | 26.11% | 11.04% | 20.4% | 9.89% | 5.94% | 7.83% | 7.98% | 7.66% | 8.23% |
| Operating Income Growth % | 2203.92% | 93.17% | -48.04% | 202.37% | -56.76% | -28.74% | 73.65% | 24.91% | 15.7% | - |
| EBITDA | 11.37M | 20.83M | 15.26M | 36.36M | 22.89M | 23.88M | 36.19M | 43.27M | 49.32M | 45.97M |
| EBITDA Margin % | 24.22% | 31.91% | 19.01% | 27.69% | 19.56% | 17.2% | 19.78% | 19.29% | 18.25% | 16.04% |
| EBITDA Growth % | 529.05% | 83.23% | -26.75% | 138.34% | -37.05% | 4.32% | 51.55% | 19.55% | 13.99% | 1.64% |
| D&A (Non-Cash Add-back) | 2.54M | 3.78M | 6.4M | 9.58M | 11.31M | 15.63M | 21.86M | 25.37M | 28.61M | 22.39M |
| EBIT | 8.82M | 10.11M | 9.11M | 26.87M | 12.82M | 9.19M | 14.81M | 16.95M | 22.95M | 19.11M |
| Net Interest Income | -272K | -181K | -314K | -509K | -318K | -197K | -424K | -776K | -1.18M | -1M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 272K | 181K | 314K | 509K | 318K | 197K | 424K | 776K | 1.18M | 1.31M |
| Other Income/Expense | -633K | -386K | -61K | -418K | 923K | 738K | 61K | -1.73M | 1.06M | -1.49M |
| Pretax Income | 8.19M▲ 0% | 10.34M▲ 26.2% | 8.8M▼ 14.9% | 26.36M▲ 199.7% | 12.5M▼ 52.6% | 8.99M▼ 28.1% | 14.39M▲ 60.1% | 16.17M▲ 12.4% | 21.77M▲ 34.6% | 22.1M▲ 0% |
| Pretax Margin % | 17.45% | 15.84% | 10.96% | 20.08% | 10.68% | 6.48% | 7.86% | 7.21% | 8.05% | 7.71% |
| Income Tax | 15K | 162K | 271K | -5.17M | 3.38M | 2.77M | 4.15M | 4.76M | 6.39M | 6.72M |
| Effective Tax Rate % | 0.18% | 1.57% | 3.08% | -19.6% | 27.01% | 30.79% | 28.82% | 29.44% | 29.36% | 30.4% |
| Net Income | 8.18M▲ 0% | 10.18M▲ 24.5% | 8.53M▼ 16.2% | 31.53M▲ 269.9% | 9.13M▼ 71.1% | 6.22M▼ 31.8% | 10.24M▲ 64.6% | 11.27M▲ 10.0% | 14.93M▲ 32.6% | 14.89M▲ 0% |
| Net Margin % | 17.42% | 15.59% | 10.62% | 24.01% | 7.8% | 4.48% | 5.6% | 5.02% | 5.53% | 5.2% |
| Net Income Growth % | 565.8% | 24.47% | -16.23% | 269.85% | -71.06% | -31.82% | 64.63% | 9.98% | 32.57% | 21.19% |
| Net Income (Continuing) | 8.18M | 9.51M | 8.53M | 31.53M | 9.13M | 6.22M | 10.24M | 11.41M | 15.38M | 15.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.91M | 1.98M | 1.93M |
| EPS (Diluted) | 0.22▲ 0% | 0.26▲ 18.2% | 0.22▼ 15.4% | 0.82▲ 272.7% | 0.22▼ 73.2% | 0.15▼ 31.8% | 0.25▲ 66.7% | 0.28▲ 12.0% | 0.37▲ 32.1% | 0.37▲ 0% |
| EPS Growth % | 579.01% | 18.18% | -15.38% | 272.73% | -73.17% | -31.82% | 66.67% | 12% | 32.14% | 25.92% |
| EPS (Basic) | 0.22 | 0.27 | 0.23 | 0.86 | 0.23 | 0.15 | 0.27 | 0.29 | 0.38 | - |
| Diluted Shares Outstanding | 37.97M | 39.68M | 39.75M | 40.53M | 40.68M | 39.81M | 40.38M | 40.8M | 40.82M | 40.49M |
| Basic Shares Outstanding | 37.91M | 37.89M | 37.72M | 38.74M | 39.49M | 38.66M | 38.35M | 38.76M | 38.9M | 38.43M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
Viemed Healthcare, Inc. (VMD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 17M | 22.96M | 27.81M | 47.17M | 47.31M | 39.74M | 38.37M | 52.88M | 48.49M | 49.81M |
| Cash & Short-Term Investments | 5.1M | 10.41M | 13.36M | 30.98M | 28.41M | 16.91M | 12.84M | 17.54M | 13.5M | 9.76M |
| Cash Only | 5.1M | 10.41M | 13.36M | 30.98M | 28.41M | 16.91M | 12.84M | 17.54M | 13.5M | 9.76M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 9.78M | 8.84M | 11.53M | 12.37M | 14.72M | 15.4M | 18.45M | 24.91M | 25.59M | 31.18M |
| Days Sales Outstanding | 76.08 | 49.43 | 52.46 | 34.39 | 45.88 | 40.5 | 36.8 | 40.55 | 34.55 | 35.87 |
| Inventory | 1.63M | 2.89M | 1.36M | 2.31M | 2.46M | 3.57M | 4.63M | 4.32M | 5.05M | 5.18M |
| Days Inventory Outstanding | 48.41 | 63.14 | 20.47 | 16.47 | 20.54 | 24.09 | 24.05 | 17.32 | 16.04 | 14.84 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 3.85M | 2.45M | 6.11M | 4.36M | 3.69M |
| Total Non-Current Assets | 20.69M | 30.56M | 54.78M | 65.39M | 70.65M | 77.3M | 116.53M | 124.19M | 166.45M | 97.74M |
| Property, Plant & Equipment | 20.69M | 30.56M | 54.77M | 55.06M | 62.85M | 68.44M | 76.85M | 79.16M | 82.36M | 79.31M |
| Fixed Asset Turnover | 2.27x | 2.14x | 1.47x | 2.39x | 1.86x | 2.03x | 2.38x | 2.83x | 3.28x | 3.49x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 29.77M | 32.99M | 58.94M | 58.94M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 567K | 848K | 1.28M | 1.22M |
| Long-Term Investments | 0 | 0 | 13K | 733K | 2.16M | 4.16M | 3.9M | 2.79M | 2.79M | 11.18M |
| Other Non-Current Assets | 0 | 0 | 0 | 863K | 862K | 1.59M | 887K | 0 | 15.79M | -34.02M |
| Total Assets | 37.69M▲ 0% | 53.52M▲ 42.0% | 82.6M▲ 54.3% | 112.56M▲ 36.3% | 117.96M▲ 4.8% | 117.04M▼ 0.8% | 154.9M▲ 32.3% | 177.07M▲ 14.3% | 214.94M▲ 21.4% | 147.55M▲ 0% |
| Asset Turnover | 1.25x | 1.22x | 0.97x | 1.17x | 0.99x | 1.19x | 1.18x | 1.27x | 1.26x | 1.53x |
| Asset Growth % | 52.73% | 42.01% | 54.31% | 36.28% | 4.8% | -0.78% | 32.34% | 14.32% | 21.39% | 36.21% |
| Total Current Liabilities | 13.15M | 16.98M | 25.91M | 23.02M | 17.81M | 18.86M | 32.12M | 37.33M | 41.06M | 40.71M |
| Accounts Payable | 3.39M | 5.88M | 5.72M | 3.35M | 5.25M | 4.9M | 7.41M | 5.32M | 7.33M | 0 |
| Days Payables Outstanding | 100.37 | 128.69 | 86.14 | 23.87 | 43.9 | 33.05 | 38.51 | 21.33 | 23.31 | 21.41 |
| Short-Term Debt | 0 | 0 | 1.75M | 1.84M | 1.48M | 0 | 1.07M | 409K | 2.29M | 2.07M |
| Deferred Revenue (Current) | 5.22M | 152K | 3.31M | 3.41M | 3.75M | 4.62M | 6.21M | 6.69M | 7.52M | 30M |
| Other Current Liabilities | 300K | -2.11M | 3.13M | 4.49M | 2.34M | 3.19M | 6.52M | 0 | 23.91M | 31.16M |
| Current Ratio | 1.29x | 1.35x | 1.07x | 2.05x | 2.66x | 2.11x | 1.19x | 1.42x | 1.18x | 1.18x |
| Quick Ratio | 1.17x | 1.18x | 1.02x | 1.95x | 2.52x | 1.92x | 1.05x | 1.30x | 1.06x | 1.06x |
| Cash Conversion Cycle | 24.11 | -16.12 | -13.21 | 26.99 | 22.53 | 31.54 | 22.34 | 36.53 | 27.29 | 29.3 |
| Total Non-Current Liabilities | 798K | 1.51M | 12.98M | 7.85M | 5.33M | 1.09M | 8.88M | 6.44M | 30.37M | 10.37M |
| Long-Term Debt | 0 | 0 | 7.63M | 5.8M | 4.31M | 0 | 6M | 3.59M | 11.29M | 10.37M |
| Capital Lease Obligations | 798K | 394K | 3.04M | 762K | 268K | 199K | 2.32M | 2.01M | 2.36M | 6.47M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15.79M | 15.79M |
| Other Non-Current Liabilities | 0 | 1.12M | 2.32M | 1.29M | 757K | 889K | 558K | 846K | 922K | 2.15M |
| Total Liabilities | 13.95M | 18.49M | 38.9M | 30.87M | 23.14M | 19.95M | 41M | 43.77M | 71.42M | 10.86M |
| Total Debt | 5.18M | 3.42M | 19.51M | 11.13M | 6.52M | 694K | 10.32M | 6.87M | 15.95M | 12.44M |
| Net Debt | 81K | -6.99M | 6.16M | -19.85M | -21.89M | -16.22M | -2.52M | -10.67M | 2.45M | 2.67M |
| Debt / Equity | 0.22x | 0.10x | 0.45x | 0.14x | 0.07x | 0.01x | 0.09x | 0.05x | 0.11x | 0.11x |
| Debt / EBITDA | 0.46x | 0.16x | 1.28x | 0.31x | 0.28x | 0.03x | 0.29x | 0.16x | 0.32x | 0.27x |
| Net Debt / EBITDA | 0.01x | -0.34x | 0.40x | -0.55x | -0.96x | -0.68x | -0.07x | -0.25x | 0.05x | 0.05x |
| Interest Coverage | 32.44x | 55.86x | 29.01x | 52.79x | 40.32x | 46.63x | 34.94x | 21.84x | 19.42x | 14.61x |
| Total Equity | 23.74M▲ 0% | 35.03M▲ 47.5% | 43.7M▲ 24.7% | 81.69M▲ 86.9% | 94.82M▲ 16.1% | 97.09M▲ 2.4% | 113.89M▲ 17.3% | 133.3M▲ 17.0% | 143.52M▲ 7.7% | 145.8M▲ 0% |
| Equity Growth % | 84.35% | 47.54% | 24.74% | 86.94% | 16.07% | 2.4% | 17.3% | 17.04% | 7.67% | 38.02% |
| Book Value per Share | 0.63 | 0.88 | 1.10 | 2.02 | 2.33 | 2.44 | 2.82 | 3.27 | 3.52 | 3.60 |
| Total Shareholders' Equity | 23.74M | 35.03M | 43.7M | 81.69M | 94.82M | 97.09M | 113.89M | 131.39M | 141.54M | 143.86M |
| Common Stock | 67K | 71K | 3.37M | 9.18M | 14.01M | 15.12M | 18.7M | 23.36M | 16.91M | 20.81M |
| Retained Earnings | 20.99M | 29.57M | 34.11M | 65.64M | 73.33M | 69.85M | 79.5M | 89.69M | 102.89M | 105.47M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5.73M | -8.82M | -157K | -451K | -278K | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.91M | 1.98M | 1.93M |
Viemed Healthcare, Inc. (VMD) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 12.02M | 22.37M | 19.09M | 35.11M | 22.49M | 27.75M | 45.21M | 39.09M | 51.92M | 51.92M |
| Operating CF Margin % | 25.62% | 34.27% | 23.78% | 26.74% | 19.22% | 19.99% | 24.7% | 17.43% | 19.21% | - |
| Operating CF Growth % | 87.46% | 86.03% | -14.67% | 83.95% | -35.93% | 23.36% | 62.94% | -13.54% | 32.81% | 270.3% |
| Net Income | 8.18M | 10.18M | 8.53M | 31.53M | 9.13M | 6.22M | 10.24M | 11.41M | 14.93M | 14.89M |
| Depreciation & Amortization | 2.54M | 3.78M | 6.4M | 9.58M | 11.31M | 15.63M | 21.86M | 25.37M | 28.61M | 29.62M |
| Stock-Based Compensation | 828K | 2.7M | 3.89M | 4.88M | 5.15M | 5.2M | 5.85M | 6.29M | 9.13M | 9.27M |
| Deferred Taxes | 0 | 0 | 0 | -8.73M | 3.88M | 1.75M | -1.44M | -3.84M | 3.11M | 3.11M |
| Other Non-Cash Items | 5.34M | 6.45M | 9.81M | 8.05M | 6.58M | 9.08M | 921K | -488K | -1.57M | -4.17M |
| Working Capital Changes | -4.87M | -748K | -9.53M | -10.2M | -13.56M | -10.13M | 7.78M | 355K | -2.3M | 4.14M |
| Change in Receivables | -10.13M | -5.25M | -12.51M | -9.96M | -7.34M | -12.57M | -1.08M | -6.07M | 1.16M | -2.56M |
| Change in Inventory | 5K | -1.25M | -306K | -2.3M | -212K | 301K | -480.65K | 574K | 59K | 113K |
| Change in Payables | 900K | 2.5M | 783K | 213K | 133K | -318K | -874.75K | 359K | 479K | -697K |
| Cash from Investing | -3.57M | -5.3M | -12.81M | -8.41M | -19.75M | -23.98M | -52.11M | -30.7M | -50.17M | -47.12M |
| Capital Expenditures | -4M | -6.11M | -13.38M | -13.04M | -19.74M | -22.9M | -26.09M | -37.77M | -39.98M | -31.21M |
| CapEx % of Revenue | 8.53% | 9.37% | 16.68% | 9.93% | 16.87% | 16.49% | 14.26% | 16.84% | 14.79% | - |
| Acquisitions | 430K | 813K | 587.34K | -629K | -599K | -141K | -28.59M | -3M | -26.33M | -19.93M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 430K | 813K | -13.34K | 5.26M | 596K | 1.06M | 2.57M | 9.32M | 16.15M | 4.02M |
| Cash from Financing | -7.69M | -11.75M | -3.33M | -9.07M | -5.32M | -15.27M | 2.83M | -3.69M | -5.79M | -10.41M |
| Debt Issued (Net) | -7.69M | -10.16M | -2.21M | -10.95M | -4M | -5.84M | 2.12M | -3.41M | 8.15M | 8.37M |
| Equity Issued (Net) | 0 | -1.59M | -1.52M | 0 | -1.43M | -9.71M | -594K | -1.07M | -11.79M | -11.97M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -1.59M | -1.52M | 0 | -1.43M | -9.71M | -594K | -1.07M | -13.22M | -13.33M |
| Other Financing | 0 | 4K | 396K | 1.88M | 112K | 283K | 1.3M | 789K | -2.16M | -6.81M |
| Net Change in Cash | 759K▲ 0% | 5.32M▲ 600.3% | 2.94M▼ 44.6% | 17.63M▲ 499.1% | -2.57M▼ 114.6% | -11.49M▼ 346.7% | -4.08M▲ 64.5% | 4.7M▲ 215.4% | -4.04M▼ 185.9% | -398K▲ 0% |
| Free Cash Flow | 8.02M▲ 0% | 16.25M▲ 102.6% | 5.7M▼ 64.9% | 22.07M▲ 287.0% | 2.75M▼ 87.5% | 4.85M▲ 76.3% | 19.12M▲ 294.2% | 1.32M▼ 93.1% | 11.93M▲ 805.2% | 25.92M▲ 0% |
| FCF Margin % | 17.09% | 24.9% | 7.1% | 16.8% | 2.35% | 3.49% | 10.45% | 0.59% | 4.41% | 9.04% |
| FCF Growth % | 69.22% | 102.64% | -64.92% | 286.99% | -87.53% | 76.3% | 294.21% | -93.11% | 805.24% | 499.98% |
| FCF per Share | 0.21 | 0.41 | 0.14 | 0.54 | 0.07 | 0.12 | 0.47 | 0.03 | 0.29 | 0.29 |
| FCF Conversion (FCF/Net Income) | 1.47x | 2.20x | 2.24x | 1.11x | 2.46x | 4.46x | 4.41x | 3.47x | 3.48x | 1.74x |
| Interest Paid | 0 | 193K | 333K | 559K | 351K | 0 | 851K | 950K | 0 | 749K |
| Taxes Paid | 0 | 151K | 338K | 3.31M | 1.77M | 0 | 3.57M | 6.83M | 0 | 4.43M |
Viemed Healthcare, Inc. (VMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 44.65% | 34.63% | 21.66% | 50.29% | 10.34% | 6.48% | 9.71% | 9.11% | 10.79% | 10.52% |
| Return on Invested Capital (ROIC) | 34.06% | 49.29% | 17.05% | 35.96% | 12.89% | 8.05% | 11.18% | 11.47% | 11.57% | 11.57% |
| Gross Margin | 73.76% | 74.43% | 69.78% | 61.01% | 62.71% | 60.99% | 61.63% | 59.4% | 57.52% | 57.46% |
| Net Margin | 17.42% | 15.59% | 10.62% | 24.01% | 7.8% | 4.48% | 5.6% | 5.02% | 5.53% | 5.2% |
| Debt / Equity | 0.22x | 0.10x | 0.45x | 0.14x | 0.07x | 0.01x | 0.09x | 0.05x | 0.11x | 0.11x |
| Interest Coverage | 32.44x | 55.86x | 29.01x | 52.79x | 40.32x | 46.63x | 34.94x | 21.84x | 19.42x | 14.61x |
| FCF Conversion | 1.47x | 2.20x | 2.24x | 1.11x | 2.46x | 4.46x | 4.41x | 3.47x | 3.48x | 1.74x |
| Revenue Growth | 49.66% | 39.09% | 22.96% | 63.61% | -10.85% | 18.6% | 31.82% | 22.54% | 20.52% | 23.1% |
Viemed Healthcare, Inc. (VMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 5, 2026·SEC
Mar 16, 2026·SEC
Mar 4, 2026·SEC
Viemed Healthcare, Inc. (VMD) stock FAQ — growth, dividends, profitability & financials explained
Viemed Healthcare, Inc. (VMD) reported $286.6M in revenue for fiscal year 2025. This represents a 1130% increase from $23.3M in 2014.
Viemed Healthcare, Inc. (VMD) grew revenue by 20.5% over the past year. This is strong growth.
Yes, Viemed Healthcare, Inc. (VMD) is profitable, generating $14.9M in net income for fiscal year 2025 (5.5% net margin).
Viemed Healthcare, Inc. (VMD) has a return on equity (ROE) of 10.8%. This is reasonable for most industries.
Viemed Healthcare, Inc. (VMD) generated $25.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Viemed Healthcare, Inc. (VMD) financial analysis — history, returns, DCA and operating performance tools
Historical returns with dividends reinvested
Dollar cost averaging vs lump sum
Yield, growth, payout safety & DRIP
EPS trends, net income & profitability
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of market, efficiency and balance-sheet ratios
DCF intrinsic value, peer multiples & estimates